About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a company based in Edmonton (Canada) founded in 1993. The company has 130 employees as of December 31, 2024. Aurinia Pharmaceuticals has completed 1 acquisition, including Kezar Life Sciences. Aurinia Pharmaceuticals offers products and services including LUPKYNIS. Aurinia Pharmaceuticals operates in a competitive market with competitors including Moderna, Forge Biologics, Annexon, Ventyx Biosciences and Dren Bio, among others.
- Headquarter Edmonton, Canada
- Employees 130 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aurinia Pharmaceuticals Inc
-
Annual Revenue
$235.13 M (USD)33.97as on Dec 31, 2024
-
Net Profit
$5.75 M (USD)107.37as on Dec 31, 2024
-
EBITDA
$33.52 M (USD)146.77as on Dec 31, 2024
-
Latest Funding Round
$28.75 M (USD), Post-IPO
Dec 28, 2016
-
Investors
Mogo
& 9 more
-
Employee Count
130
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AUPH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals offers a comprehensive portfolio of products and services, including LUPKYNIS.
Treatment for lupus nephritis to prevent kidney damage in patients.
People of Aurinia Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
31 people
Software Development Team
10 people
Operations Team
8 people
Finance and Accounting
7 people
Sales and Marketing
6 people
Scientific Team
5 people
Field Team
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of Aurinia Pharmaceuticals
Investors in Aurinia Pharmaceuticals
Aurinia Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Mogo, RA Capital and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Aurinia Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aurinia Pharmaceuticals
Aurinia Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kezar Life Sciences.
Investment portfolio details for Aurinia Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drugs targeting protein homeostasis for autoimmune disorders are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Aurinia Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aurinia Pharmaceuticals
Detailed financials for Aurinia Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aurinia Pharmaceuticals Comparisons
Peer comparison for Aurinia Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Forge Biologics, Annexon, Ventyx Biosciences and Dren Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Aurinia Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aurinia Pharmaceuticals
Complete news archive for Aurinia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals was founded in 1993 and raised its 1st funding round 20 years after it was founded.
Aurinia Pharmaceuticals is headquartered in Edmonton, Canada. It is registered at Edmonton, Alberta, Canada.
As of Dec 31, 2024, the latest employee count at Aurinia Pharmaceuticals is 130.
Annual revenue of Aurinia Pharmaceuticals is $235.13M as on Dec 31, 2024.
Aurinia Pharmaceuticals was founded in 1993 in Edmonton, Canada, and operates in the pharmaceutical sector focused on autoimmune conditions. Therapeutics are developed, including the lead candidate voclosporin for lupus nephritis treatment. Additional pipeline assets encompass AUR200, an immune modulator targeting BAFF and APRIL activity, and AUR300, a peptide designed for autoimmune and fibrotic diseases. Operations center on advancing these candidates through clinical development.
Aurinia Pharmaceuticals's top competitors include Moderna, Forge Biologics and Annexon.
Aurinia Pharmaceuticals offers LUPKYNIS.
Yes, Aurinia Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AUPH.
Aurinia Pharmaceuticals has made 1 acquisition, including Kezar Life Sciences.
Aurinia Pharmaceuticals has 10 investors. Key investors include Mogo, RA Capital, Abingworth, ILJIN, and venBio.
The ticker symbol of Aurinia Pharmaceuticals is AUPH on NASDAQ.